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Icodextrin (ICO) has been a major addition to the man-agement of ultrafiltration (UF) in peritoneal dialysis
(PD), allowing sustained UF during long dwells and main-
tenance of UF in the face of increased membrane solute
transport, while minimizing the deleterious effects of
local and systemic glucose exposure. Initial studies in-
dicated ICO typically achieved UF over 500 mL (1–4), but
these studies were mostly using the overnight dwell of
continuous ambulatory PD and may not always have
taken overfill into account. An increasing number of
studies are reporting greater variation in achieved UF,
particularly in automated PD patients that use a longer
dwell (3–5). This runs counter to the UF with ICO previ-
ously predicted by computer-generated three-pore mod-
eling, which suggested UF should increase linearly up to
at least 17 hours. Given the importance of UF and the
widespread use of ICO, this is an area requiring further
clarification.
WHAT IS THE EVIDENCE FOR VARIABILITY OF UF WITH ICO?
This variability was first noted by us in 2004 when ana-
lyzing 9-hour dwells: a median volume of 370 mL UF was
observed but with significant variation between indi-
viduals, with volumes ranging from >500 mL of net fluid
reabsorption to >1000 mL UF. Some variation within in-
dividuals was also noted but to a lesser degree than the
between-patient variation.
The factors underlying this variation remain unclear
and the study by Jeloka et al. (6), on which Venturoli
et al.’s work published in this issue of Peritoneal Dialysis
International (7) was based, attempted to investigate
some of these factors. Canadian and Turkish PD patients
(n = 36) were given ICO in gradually increasing dwell
lengths (from 10 to 14 hours). Mean achieved UF ranged
from 352 mL at 10 hours to 390 mL at 13 hours but the
standard deviation was consistently around 250 mL, with
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the minima being >300 mL reabsorption and the maxi-
ma 1012 – 1240 mL. There was no correlation with dwell
length and the only significant finding was an associa-
tion between increased mean UF and either male gender
or high transport characteristics. Median within-patient
standard deviations were 104 mL whereas the between-
patient standard deviations were 267 mL, confirming the
earlier observation that there is a high degree of be-
tween-patient variability in UF achieved with ICO.
WHAT FACTORS COULD BE AFFECTING UF WITH ICO?
The three-pore model is currently the only mathemati-
cal description of membrane function that can provide
both an accurate explanation for and a prediction of the
UF achieved with either glucose or ICO dialysis fluids.
Furthermore, the model is also able to predict UF pro-
files when ICO is combined with glucose. For example,
computer-based modeling with the three-pore model was
used to suggest different concentrations of the combi-
nation that would result in improved UF, and was subse-
quently shown experimentally to be correct (8,9).
According to the three-pore model, ICO will, through
its colloid osmotic pressure (COP), act across small pores
to achieve UF with negligible effect across the ultrasmall
pores (aquaporins). Factors that could potentially affect
the degree of UF will therefore include the number of
small pores (broadly equivalent to membrane transport
status), the UF coefficient of the membrane (LpS), and
factors affecting the colloidal concentrations on either
side of the membrane, that is, plasma COP and the me-
tabolism or clearance of ICO itself. Additional factors that
will also affect the net achieved volume of UF will include
the intraperitoneal hydrostatic pressure opposing the
COP gradient, the “lymphatic” reabsorption rate, and,
importantly, the presence of any leaks from the abdomi-
nal cavity.
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intraperitoneal pressure on net UF achieved with glu-
cose or ICO confirmed the negative association with the
former but found no relationship with the latter (14).
However, these results should be interpreted with cau-
tion, especially when extrapolating to adults, as obser-
vations were limited to 4-hour dwells and it is known that
children achieve less UF with ICO than seen in the adult
population (15).
As ICO exerts its main effects by creating a COP gra-
dient across the peritoneum, it follows that this will,
in turn, be affected by the intracapillary COP exerted
by plasma proteins. The relationship between protein
concentration and COP is not straightforward — al-
bumin possesses approximately twice the COP per
gram compared with globulins — and several equa-
tions have been described to predict COP from either
total protein or albumin. One equation has been de-
rived for nephrotic patients using both albumin and
fibrinogen (16) but there have been no studies ex-
amining the true plasma COP in PD patients, a group
known to have abnormal protein kinetics with dialytic
protein loss.
Plasma COP has been noted to vary diurnally, with
hemolysis, with recumbence, and with fasting (17,18).
Changes in intravascular volume, which may reflect ex-
tracellular volume, will also affect plasma COP as with
WHAT EFFECT COULD MEMBRANE FACTORS HAVE?
According to the three-pore model, “high transport
status” corresponding to a high permeability–surface
area product (PS) — also known as mass transfer area
coefficient (MTAC) — represents a greater capillary sur-
face area and therefore a larger small pore area. As ICO’s
main effect on UF is across the small pores, this means
that, not only should patients with a high transport sta-
tus achieve a better UF with ICO versus glucose, but that
they should achieve a greater UF with ICO than would
patients with low transport status with ICO. The former
point is well established but there is also evidence for
the latter, with both our observations reported here and
Jeloka’s work demonstrating a greater UF with high
transport status. However, only a small amount of UF
variation could be attributed to this in both cases, indi-
cating that transport status has only a minor role in de-
termining the variability of UF with ICO.
Hydraulic permeability (Lp) is a measure of the
membrane’s permeability to water per unit area and,
when multiplied by surface area, this gives LpS (also
called LpA), commonly called the UF coefficient. There
is increasing evidence that the more severe type 2 UF
failure seen after prolonged PD, associated not just with
high solute transport but also with reduction in the os-
motic conductance of the membrane (10) and thought
to be associated with the development of fibrosis (11),
could be due to reduced LpS. This could be the explana-
tion of our own observation that the net achieved UF with
ICO is less in long-term PD patients (see Figure 1). How-
ever, no studies to date have correlated LpS with UF from
ICO, but this has clear potential to be one of the sources
of variation and warrants further investigation.
WHAT EFFECT COULD DIFFERENT HYDROSTATIC AND OSMOTIC
PRESSURES HAVE?
While the intrinsic characteristics of the membrane
will affect how efficiently water flows through it, the
balance of the hydrostatic, crystalloid, and colloid pres-
sure gradients determine the quantity and direction of
flow. The formulation of icodextrin PD solution is iso-
osmotic with plasma so, unless there is significant intra-
peritoneal metabolism (see below), this should have
little effect. An elevated intraperitoneal hydrostatic
pressure will favor fluid reabsorption by whatever route
(transcapillary or lymphatic), potentially increasing as
the volume of fluid within the peritoneum increases.
Several studies have shown hydrostatic pressure to have
a significant effect on net UF with glucose exchanges
(12,13). One study in children comparing the effect of
Figure 1 — Net ultrafiltration achieved over 9 hours in CAPD
(corrected for overfill) and APD patients according to length
of time on treatment. Multivariate analysis indicated that
length of time on treatment was associated with less (p <
0.001), whereas high solute transport was associated with
more ultrafiltration (p = 0.031). ICO = icodextrin; UF = ultra-
filtration; CAPD = continuous ambulatory peritoneal dialysis;
APD = automated PD. (Stompor and Davies; previously pub-
lished in abstract form only).
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more volume there is more water to dilute the proteins
and decrease the plasma COP. Theoretically, patients with
fluid overload could achieve better UF with ICO. This is
supported by the randomized trials investigating the
effect of ICO on fluid status where the greatest improve-
ment was seen in the most overhydrated patients at the
start of the studies (19,20). Conversely, with a greater
degree of UF, extracellular volume will contract, poten-
tially inhibiting further UF by producing a higher plasma
COP, although plasma albumin concentration did not
change in these intervention studies. However, the ef-
fect of plasma COP on UF has not been examined and this
could possibly explain some of both the intra- and the
interindividual variation.
WHAT EFFECTS COULD THE METABOLISM AND CLEARANCE OF
ICO HAVE?
Rates of metabolism and clearance of ICO could af-
fect UF in two ways. First, metabolites of ICO are found
in the plasma, thereby potentially increasing the crys-
talloid osmotic pressure of plasma and opposing UF out
of the capillaries. Second, clearance of ICO will decrease
the intraperitoneal COP by which ICO exerts its effect
on UF.
Icodextrin is a mix of different length polymers of
glucose whose primary route of degradation is thought
to be by plasma amylase producing shorter polymers.
These shorter polymers are then metabolized by tissue
maltases, which break these short polymers down to
glucose. Amylase levels are high in predialysis, hemo-
dialysis, and PD patients on glucose-only dialysis but
are strikingly reduced in patients on ICO. This discrep-
ancy was previously thought to reflect interference with
the assay by ICO metabolites present in the plasma but
more recent evidence suggests this is not necessarily
the case (21) and the reason remains unclear. The over-
all impact of plasma amylase and low molecular weight
ICO metabolites in plasma was investigated in a sec-
ondary analysis of a randomized controlled trial that
demonstrated no correlation between either of these
and changes in fluid status (20).
Clearance of ICO from the peritoneal cavity follows
zero-order kinetics, with the amount absorbed being
directly proportional to the dwell length, which is con-
sistent with convective flow. At 8 hours, approximately
20% of ICO has been cleared, and at 16 hours, 40%.
This does not specify the route of clearance, which will
be partially through lymphatics but could also include
penetration into the interstitium, where it may be me-
tabolized, and leaks by any anatomic route. The true
proportion of clearance via these different pathways is
unclear as their direct measurement is technically
difficult.
The frequency of leaks causing UF problems with
ICO is unclear but a recent presentation at an ISPD
conference reported an investigation into causes of
acute UF failure where all patients with this problem
had computerized tomographic or magnetic reso-
nance imaging of their abdomen: 64% of these pa-
tients had evidence of a retroperitoneal leak and this
leak was associated with a high odds ratio, compared
with other PD patients, of a hernia or pleuroperitoneal
leak (22). While this study requires confirmation in
other populations, it emphasizes an important clini-
cal issue where UF failure should prompt a high index
of suspicion for a leak.
WHAT DOES THE ANALYSIS BY VENTUROLI ADD TO OUR
UNDERSTANDING OF THIS COMPLEX PROBLEM?
Venturoli et al. investigated some of the possible rea-
sons for variation in UF with ICO by further analyzing
the work by Jeloka et al. Initially, using linear and qua-
dratic regression, they identified individual patterns in
UF over 10- to 14-hour dwells. Four profiles were de-
scribed: steadily increasing, steadily decreasing, con-
cave, and convex. They then sought to fit these patterns
to the three-pore model by adjusting different factors,
including UF coefficient (LpS), clearance of large mo-
lecular weight fractions of ICO from the peritoneal cav-
ity (ClLF), diffusivity of the membrane (PS or MTAC), and
transcapillary COP gradient and, using the three-pore
model, predicted UF curves. The steadily increasing and
concave curves were readily predicted with variations in
UF coefficient and diffusivity. The best fit for the steadily
decreasing curve came from variations in the trans-
capillary COP gradient, whereas the convex curve was not
predicted by any of the changes. In particular, this pro-
cess highlighted the large variation in UF predicted from
relatively minor adjustments in the transcapillary COP
gradient. The authors did not investigate the effect of
varying true lymphatic fluid reabsorption, although this
could potentially lead to variability in net UF.
The Venturoli study certainly sheds light on the way
in which we need to consider the issue of UF with ICO.
Whereas UF was previously considered to follow a simple
linear increase with dwell length, with any variation
being due simply to differences in the gradient, this is
clearly not the case, as the four different patterns be-
tween 10 and 14 hours demonstrated. The three-pore
model has again illustrated its utility by describing three
of these patterns, so suggesting possible mechanisms.
The wide variation in UF shown in previous studies could
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therefore be partly explained by differences in plasma
COP, macromolecular clearance, and LpS, although there
is still some unexplained variation. Figure 1 in Venturoli’s
paper demonstrates well the intraindividual variation
that this study has not explained, although it has high-
lighted the potential importance of plasma COP, a factor
known to vary within individuals.
HOW DOES THIS AFFECT OUR CLINICAL PRACTICE?
As most of the Venturoli paper is based on theoretical
modeling, empirical validation remains crucial. For the
time being, however, clinicians can no longer assume
that UF will simply increase with time and consideration
must now be given to the optimal length of dwell that
each patient uses for ICO. Any patient exhibiting net fluid
reabsorption with ICO should be closely investigated for
a peritoneal leak. Until we have a predictive model based
on sound clinical validation from which an “ICO perito-
neal equilibration test” can be developed, establishing
the optimal dwell length will involve nothing more so-
phisticated than trial and error.
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